These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10952609)

  • 1. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.
    Martínez-Martínez L; Conejo MC; Pascual A; Hernández-Allés S; Ballesta S; Ramírez De Arellano-Ramos E; Benedí VJ; Perea EJ
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2534-6. PubMed ID: 10952609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.
    Paltansing S; Kraakman M; van Boxtel R; Kors I; Wessels E; Goessens W; Tommassen J; Bernards A
    Microb Drug Resist; 2015 Feb; 21(1):7-16. PubMed ID: 25188329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.
    Beceiro A; Maharjan S; Gaulton T; Doumith M; Soares NC; Dhanji H; Warner M; Doyle M; Hickey M; Downie G; Bou G; Livermore DM; Woodford N
    J Antimicrob Chemother; 2011 Sep; 66(9):2006-10. PubMed ID: 21742679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-spectrum beta-lactam resistance due to AmpC hyperproduction and CMY-2 coupled with the loss of OMPK35 in Malaysian strains of Escherichia coli and Klebsiella pneumoniae.
    Palasubramaniam S; Subramaniam G; Muniandy S; Parasakthi N
    Microb Drug Resist; 2007; 13(3):186-90. PubMed ID: 17949305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE; Eng RH; Smith SM; Tan EN
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
    Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions of the AmpC beta-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to beta-lactams.
    Mazzariol A; Cornaglia G; Nikaido H
    Antimicrob Agents Chemother; 2000 May; 44(5):1387-90. PubMed ID: 10770787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
    Mammeri H; Guillon H; Eb F; Nordmann P
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4556-60. PubMed ID: 20733047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases.
    Jacoby GA; Carreras I
    Antimicrob Agents Chemother; 1990 May; 34(5):858-62. PubMed ID: 2193623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
    Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
    Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems.
    Ardanuy C; Liñares J; Domínguez MA; Hernández-Allés S; Benedí VJ; Martínez-Martínez L
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1636-40. PubMed ID: 9660996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.